Novel Designs of Early Phase Trials for Cancer Therapeutics
Editat de Shivaani Kummar, Chris Takimotoen Limba Engleză Paperback – 25 mai 2018
This book is a valuable resource for medical oncologists, basic and translational biomedical scientists, and trainees in oncology and pharmacology who are interested in learning how to improve their research by using early phase trials.
- Brings a comprehensive review and recommendations for new clinical trial designs for modern cancer therapeutics
- Provides the reader with a better understanding on how to design and implement early phase oncology trials
- Presents a better and updated understanding of the process of developing new treatments for cancer, the exciting scientific advances and how they are informing drug development
Preț: 717.78 lei
Preț vechi: 755.56 lei
-5% Nou
Puncte Express: 1077
Preț estimativ în valută:
137.43€ • 143.11$ • 114.03£
137.43€ • 143.11$ • 114.03£
Carte tipărită la comandă
Livrare economică 07-21 februarie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780128125120
ISBN-10: 0128125128
Pagini: 234
Dimensiuni: 191 x 235 mm
Greutate: 0.48 kg
Editura: ELSEVIER SCIENCE
ISBN-10: 0128125128
Pagini: 234
Dimensiuni: 191 x 235 mm
Greutate: 0.48 kg
Editura: ELSEVIER SCIENCE
Public țintă
medical oncologists; translational biomedical researchers; graduate students on oncology, pharmacology, regulatory affairs and patient reported outcomesCuprins
Introduction: Changing landscape of phase I trials1. Phase I trial designs: Past, Present, and Future2. Statistical perspectives on cohort expansions in early phase trials3. Determining the optimal dose and schedule4. Conducting large phase I trials with multiple expansion cohorts5. Role and application of molecular profiling in early phase trials6. Novel trial designs for immunotherapies7. Designing trials for cell based therapies8. Evaluating novel drug combinations in early phase trials9. Integrating biomarkers in early phase trials: developing the evidence base for ‘actionable’ biomarkers10. Novel imaging endpoints in early phase trials11. Developing a novel agent: the regulatory process perspective12. Conducting proof of concept phase I trials-Regulatory Implications13. Efficacy endpoints in early phase trials14. Incorporation of Patient Reported Outcomes in early phase trials